Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.

Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Dowsett M, Landberg G; TransATAC investigators.

Breast Cancer Res. 2012 Apr 4;14(2):R57.

2.

Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

Aapro MS, Forbes JF.

Breast Cancer Res Treat. 2003;80 Suppl 1:S3-11; discussion S13-8. Review.

PMID:
14535530
3.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
4.

Obesity and endocrine therapy: host factors and breast cancer outcome.

Goodwin PJ.

Breast. 2013 Aug;22 Suppl 2:S44-7. doi: 10.1016/j.breast.2013.07.008. Review.

PMID:
24074791
5.

Role of anastrozole in adjuvant therapy for postmenopausal patients.

Buzdar AU.

Semin Oncol. 2003 Oct;30(5 Suppl 16):21-9. Review.

PMID:
14613023
6.

Current and future status of adjuvant therapy for breast cancer.

Coleman RE.

Cancer. 2003 Feb 1;97(3 Suppl):880-6. Review.

7.

Focus on anastrozole and breast cancer.

Mokbel K.

Curr Med Res Opin. 2003;19(8):683-8. Review.

PMID:
14687437
8.

Breast cancer chemoprevention--an update.

Mokbel K, Singh-Ranger G.

Curr Med Res Opin. 2002;18(6):329-31. Review.

PMID:
12442878
9.

New developments in the treatment of postmenopausal breast cancer.

Howell A.

Trends Endocrinol Metab. 2005 Nov;16(9):420-8. Epub 2005 Oct 6. Review.

PMID:
16213745
10.
12.
13.

Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.

Brufsky AM.

Am J Clin Oncol. 2014 Aug;37(4):404-10. doi: 10.1097/COC.0000000000000086. Review.

14.

Examining the role of cyclin D1 in breast cancer.

Velasco-Velázquez MA, Li Z, Casimiro M, Loro E, Homsi N, Pestell RG.

Future Oncol. 2011 Jun;7(6):753-65. doi: 10.2217/fon.11.56. Review.

PMID:
21675838
15.

[A case of local recurrence developing thirty-nine years after mastectomy for breast cancer].

Tashima Y, Kawano K.

Gan To Kagaku Ryoho. 2014 Mar;41(3):357-9. Review. Japanese.

PMID:
24743283
16.

[Gene expression classifiers in the prognosis of breast cancer].

Drukker CA, Schmidt MK, van Dalen T, van der Hoeven JJ, Linn SC, Rutgers EJ.

Ned Tijdschr Geneeskd. 2014;158:A7001. Review. Dutch.

PMID:
24780571
17.

The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer.

Folkerd EJ, Martin LA, Kendall A, Dowsett M.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):250-5. Epub 2006 Oct 17. Review.

PMID:
17049846
18.

[Molecular prognostic and predictive markers of breast cancer treatment].

de Cremoux P.

Bull Cancer. 2010 Nov;97(11):1297-304. doi: 10.1684/bdc.2010.1207. Review. French.

19.

When tamoxifen turns bad.

Horwitz KB.

Endocrinology. 1995 Mar;136(3):821-3. Review. No abstract available.

PMID:
7867589
20.

An update on the implications of cyclin D1 in oral carcinogenesis.

Ramos-García P, Gil-Montoya JA, Scully C, Ayén A, González-Ruiz L, Navarro-Triviño FJ, González-Moles MA.

Oral Dis. 2017 Oct;23(7):897-912. doi: 10.1111/odi.12620. Epub 2017 Mar 31. Review.

PMID:
27973759

Supplemental Content

Support Center